Iconic La Liga Defender Opens Up About Health Diagnosis

Atlético Madrid stalwart José María Giménez, who spent 13 seasons with the capital club, has recently revealed that he was diagnosed with Attention Deficit Hyperactivity Disorder (ADHD). The 31-year-old Uruguayan centre-back's admission has once again sparked debate within the psychological community regarding the accuracy of such assessments and the nature of the condition. Giménez joined Deportivo La Coruña earlier this summer.

In an interview with the Uruguayan Footballers' Association, also reported by La Opinión de A Coruña, the veteran defender shared that both he and his eight-year-old son recently received an official ADHD diagnosis. The defender recounted the experience with visible emotion:

"At school, I always did reasonably well with my classwork, but my behaviour let me down. Poor teachers, having to put up with me... When they told me it was hereditary, I broke down in tears. I had to explain it to my son: that he is special, just like his dad, and that we have to take a pill every morning."

While the revelation drew widespread empathy from the public, it also rekindled a long-standing scientific debate. The discussion does not question the player's personal experience, but rather addresses the wider issue of growing overdiagnosis and potential assessment inaccuracies surrounding neurodevelopmental conditions.

Controversy surrounding the condition dates back to the earliest clinical descriptions by George Still in 1902, as noted by AS. According to established researchers such as Dr. William Barbaresi and Dr. Stephen Faraone, ADHD is a genuine, universal, and chronic neurodevelopmental disorder defined by persistent patterns of inattention, hyperactivity, and impulsivity. The DSM-5 categorises it as a condition whose exact origins remain incompletely understood, despite modern MRI neuroimaging and the identification of risk factors like prenatal complications or maternal alcohol and tobacco use. Meanwhile, concerns continue to grow regarding the surge in adult diagnoses and its ties to the pharmaceutical market, particularly given that symptoms traditionally manifest during early school years.

Psychology professionals have expressed concern over the steady rise in new diagnoses. Specialist literature, such as Dykinson's Handbook of Behaviour Therapy, reports 15 million diagnosed cases in the United States and 3.3 million among children and adolescents in the European Union (with the condition persisting into adulthood in 85% of males and 61% of females). Global interest remains massive, with an average of three new scientific papers published daily. Worldwide, roughly 5% of children receive a diagnosis—a figure that halves in adulthood—even though ADHD-related consultations account for between 20% and 40% of visits in child and adolescent psychiatry.

Dissenting voices within the scientific community hold far more sceptical views. Marino Pérez, a specialist in clinical psychology, professor of psychopathology at the University of Oviedo, and co-author of Volver a la normalidad (Returning to Normalcy), took a hardline stance in an interview with Spanish newspaper ABC, arguing that ADHD does not exist as a distinct clinical entity and claiming prescribed medications function more like cognitive performance enhancers than genuine medical treatment.

Meanwhile, experts in sports psychology and radical behaviourism advocate for a functional approach rather than medical labelling. In their view, attention should focus on the specific environmental stimuli and triggers that drive an individual's behaviour. Significant questions also remain regarding the potential side effects of widespread medication use stemming from false-positive diagnoses—a trend driven by pharmaceutical interests—when every case warrants individual, tailored analysis.

The topic of ADHD in sports, particularly in football, has fueled intense debate for years. Beyond worries over overdiagnosis and the heavy influence of the pharmaceutical sector pushing medication-first strategies, concerns also exist that a diagnosis could occasionally serve as a convenient shield for players struggling to follow tactical instructions, softening external criticism.

Public speculation has also been rife, with unverified claims frequently linking icons like Andrés Iniesta or Zinedine Zidane to the disorder, despite neither ever confirming such reports. Iniesta has always been remarkably candid about his mental health, openly discussing his battle with depression, making the absence of any mention of ADHD telling. Accurately diagnosing the condition remains difficult, as standard evaluations can initially yield inconclusive results. Nonetheless, a misconception has taken hold that any unconventional, instinct-driven footballer must inherently have hyperactivity, even as symptoms naturally evolve with age.

The widespread increase in diagnoses, highlighted by specialists such as Professors García-Peñas and Domínguez-Carral, eventually prompted international bodies to step in. In March 2015, the Standing Committee of the Parliamentary Assembly of the Council of Europe adopted Resolution 2042. The document urged member states to implement more rigorous diagnostic criteria, improve specialist training, and prioritise non-pharmacological interventions, placing neurofeedback therapy at the forefront.

How does the condition actually impact performance on the pitch? Primarily, it influences focus and sustained concentration in a high-pressure environment where players must make split-second decisions amid a constant influx of sensory stimuli. The distinction for diagnosed individuals lies in the degree of impairment and how severely it hinders their day-to-day execution, alongside genetic predispositions and potential co-occurring conditions.

Treatment typically combines cognitive behavioural therapy with medications such as methylphenidate, atomoxetine (Strattera), or lisdexamfetamine. However, administering these substances in elite sports requires strict oversight. Because several of these compounds feature on the World Anti-Doping Agency's (WADA) prohibited list, club medical staffs must secure a Therapeutic Use Exemption (TUE). This ensures players like Giménez and other professionals can follow their prescribed treatment plans without risking sanctions during routine anti-doping controls.